Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study

scientific article

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/0269881108099418
P698PubMed publication ID19074536

P50authorEduard VietaQ20090640
P2093author name stringD Keller
J Miceli
A D Loebel
P A English
T Ramey
P2860cites workWhat really matters to bipolar patients' caregivers: sources of family burden.Q51916677
Chlorpromazine Equivalent Doses for the Newer Atypical AntipsychoticsQ55969829
Atypical antipsychotics in the treatment of mood disordersQ57612899
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study GroupQ33178075
Is there a role for 5-HT1A agonists in the treatment of depression?Q34174041
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of ManiaQ34531273
Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studiesQ34558705
Molecular targets in the treatment of anxietyQ35001313
Treatment of acute mania--from clinical trials to recommendations for clinical practiceQ35965556
Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implicationsQ36550498
ManiaQ41439578
Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trialQ44385585
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar maniaQ44565868
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute maniaQ44684784
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidolQ45168624
Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trialQ46596821
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophreniaQ46628164
Risperidone in the treatment of acute mania: double-blind, placebo-controlled studyQ46681460
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trialQ46681464
Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trialQ46683979
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectplaceboQ269829
P304page(s)547-558
P577publication date2008-12-12
P1433published inJournal of PsychopharmacologyQ6295819
P1476titleZiprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study
P478volume24

Reverse relations

cites work (P2860)
Q35236966Acute and long-term treatment of mania.
Q37933405Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials
Q38884279Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management
Q38003196Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder
Q44142664Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
Q34809427Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?
Q38003197Efficacy of antimanic treatments in mixed states
Q24601815Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials
Q38012647Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Q38284625Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder
Q36588607Evidence review and clinical guidance for the use of ziprasidone in Canada
Q53080275Factors modifying drug and placebo responses in randomized trials for bipolar mania.
Q47381585Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study
Q47314501Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study
Q39049252Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder?
Q59336772Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision
Q33529314Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis
Q37960632Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review
Q37908140Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder
Q38413932Revisiting loxapine: a systematic review
Q28066714The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm
Q38003199The clinical management of bipolar disorder complexity using a stratified model
Q38132709The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study
Q37873301The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
Q38268590Weight gain and antipsychotics: a drug safety review
Q37850820Ziprasidone for maintenance treatment of bipolar I disorder in adults
Q37244876Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study
Q37336886Ziprasidone in the treatment of affective disorders: a review.

Search more.